Pharma Capsules - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Capsules
Brief pharmaceutical news items for February 2008.

Pharmaceutical Technology


Agreements

DSM Signs Supply Agreement with IEP

DSM Pharma Chemicals (Parsippany, NJ), a business unit of DSM Pharmaceutical Products, entered into an enzyme- supply agreement with IEP (Wiesbaden, Germany) to enable fast and secure scale-up of chiral alcohol manufacturing. Under the terms of the agreement, DSM Pharma Chemicals has access to IEP's alcohol dehydrogenases, as well as a supply of IEP enzymes at commercial scale. DSM can source the enzymes from IEP or produce them in its own manufacturing facilities in Delft, The Netherlands, Capua, Italy, and Seclin, France. According to Oliver May, DSM's competence manager for biocatalysis, a flexible enzyme supply chain is key to the timely delivery of products to DSM's customers.

Akrimax Purchases Wyeth Plant

Akrimax Pharmaceuticals (Cranford, NJ) acquired Wyeth's (Madison, NJ) drug-product manufacturing and packaging plant in Rouses Point, New York. The acquisition prevents the plant's closure. Wyeth had planned to phase out its operations at the Rouses Point plant because of changes in product demand and a reassessment of its manufacturing network.

Akrimax is an emerging branded-pharmaceutical company led by a management team with expertise in the development, manufacturing, distribution, marketing, and sales of pharmaceutical products.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here